195 related articles for article (PubMed ID: 17112803)
1. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
4. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
5. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
6. Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.
Benz-de Bretagne I; Zahr N; Le Gouge A; Hulot JS; Houillier C; Hoang-Xuan K; Gyan E; Lissandre S; Choquet S; Le Guellec C
Br J Clin Pharmacol; 2014 Aug; 78(2):329-42. PubMed ID: 24433481
[TBL] [Abstract][Full Text] [Related]
7. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
Haenisch S; May K; Wegner D; Caliebe A; Cascorbi I; Siegmund W
Pharmacogenet Genomics; 2008 Apr; 18(4):357-65. PubMed ID: 18334920
[TBL] [Abstract][Full Text] [Related]
8. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
9. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination.
Hulot JS; Villard E; Maguy A; Morel V; Mir L; Tostivint I; William-Faltaos D; Fernandez C; Hatem S; Deray G; Komajda M; Leblond V; Lechat P
Pharmacogenet Genomics; 2005 May; 15(5):277-85. PubMed ID: 15864128
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
11. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
12. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
13. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Haenisch S; Zimmermann U; Dazert E; Wruck CJ; Dazert P; Siegmund W; Kroemer HK; Warzok RW; Cascorbi I
Pharmacogenomics J; 2007 Feb; 7(1):56-65. PubMed ID: 16788565
[TBL] [Abstract][Full Text] [Related]
14. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.
Ansari M; Sauty G; Labuda M; Gagné V; Laverdière C; Moghrabi A; Sinnett D; Krajinovic M
Blood; 2009 Aug; 114(7):1383-6. PubMed ID: 19515727
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia.
Taub JW; Matherly LH; Ravindranath Y; Kaspers GJ; Rots MG; Zantwijk CH
Leukemia; 2002 Apr; 16(4):764-5. PubMed ID: 11960366
[No Abstract] [Full Text] [Related]
18. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.
Imanishi H; Okamura N; Yagi M; Noro Y; Moriya Y; Nakamura T; Hayakawa A; Takeshima Y; Sakaeda T; Matsuo M; Okumura K
J Hum Genet; 2007; 52(2):166-171. PubMed ID: 17180579
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.
Matherly LH; Taub JW
Leuk Lymphoma; 1996 May; 21(5-6):359-68. PubMed ID: 9172800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
